ClinicalTrials.gg
CompletedNCT02834390Updated Mar 5, 2025Results posted

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

A Phase 1 interventional study of Quizartinib and Cytarabine in Acute Myeloid Leukemia, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Daiichi Sankyo Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.

Enrollment
26th of 28
7 · median 69
Started
2016
with 3 others
Phase 1
8 of 28
1 open now
Registered
10th of 28
by date
Lead sponsor
4 of 28
Daiichi Sankyo Co., Ltd.

Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 26th largest by enrollment, is one of 4 that started in 2016, is one of 8 in phase 1, and was the 10th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About quizartinib

quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing quizartinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This is a phase 1b, dose escalation, study of quizartinib to evaluate the safety profile, the pharmacokinetics, and the recommended dose of quizartinib for subsequent clinical studies of the combination of quizartinib and induction and consolidation chemotherapy.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • AML
  • phase 1
  • hematology
  • malignancy
  • newly diagnosed
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No prior treatment for AML (including quizartinib)
  • (Eastern Cooperative Oncology Group) Performance Status of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of acute promyelocytic leukemia
  • Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Quizartinib 20 mg/day

    Participants who received 20 mg quizartinib once daily in the morning under fasting conditions. For the Induction phase, cytarabine (100 mg/m\^2/day IV) and either idarubicin (12 mg/m\^2/day IV infusion) or daunorubicin (60 mg/m\^2/day IV) were co-administered with quizartinib. For the Consolidation phase, cytarabine (3.0 g/m\^2/12 hours IV) was co-administered with quizartinib.

    Drug: Quizartinib · Drug: Cytarabine · Drug: Idarubicin · Drug: Daunorubicin

  • Experimental
    Quizartinib 40 mg/day

    Participants who received 40 mg quizartinib once daily in the morning under fasting conditions. For the Induction phase, cytarabine (100 mg/m\^2/day IV) and either idarubicin (12 mg/m\^2/day IV infusion) or daunorubicin (60 mg/m\^2/day IV) were co-administered with quizartinib. For the Consolidation phase, cytarabine (3.0 g/m\^2/12 hours IV) was co-administered with quizartinib.

    Drug: Quizartinib · Drug: Cytarabine · Drug: Idarubicin · Drug: Daunorubicin

Interventions

  • \[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21. \[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19. \[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19.

  • \[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7. \[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5. \[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5.

  • Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3. \[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2.

  • Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3. \[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2.

06

What researchers measure

Primary outcomes

  1. Summary of Best Responses After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

    Best response was defined as the best measured complete remission (CR), CR with incomplete hematological recovery (CRi), CR with incomplete platelet recovery (CRp), Partial remission (PR), or No response (NR) in the overall response assessments at all time points after the first dose. CR is defined as absence of leukemia cells morphologically; bone marrow blasts \<5 %; neutrophil count ≥ 1000 /mm 3; platelet count ≥ 100 ,000 /mm 3, independence of RBC transfusions for 4 weeks; independence of platelet transfusions for 1 week; absence of extramedullary leukemia.

    Time frame: Day 0 to Day 21 of last completed cycle (each cycle 28 days), up to approximately 1 year

  2. Summary of Best Response Rates After the First Oral Dose of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

    Best response was defined as the best measured complete remission (CR), CR with incomplete hematological recovery (CRi), CR with incomplete platelet recovery (CRp), Partial remission (PR), or No response (NR) in the overall response assessments at all time points after the first dose.

    Time frame: Day 0 to Day 21 of last completed cycle (each cycle 28 days), up to approximately 1 year

  3. Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) of Geometric Means of Quizartinib and Active Metabolite (AC886) After Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia

    The maximum serum plasma concentration (Cmax) is reported at Induction phase Cycle 1, Day 9 and the maximum serum plasma concentration at steady state (Cmax,ss) is reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.

    Time frame: Induction phase Cycle 1, Day 8 to Cycle 1, Day 21 (each cycle 28 days)

  4. Pharmacokinetic Parameter Area Under the Concentration-Time Curve During Dosing Interval of Quizartinib and Metabolite (AC886) After Daily Dose of 20 mg or 40 mg With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia

    The area under the plasma concentration-time curve during dosing interval (AUCtau) of geometric means is reported at Induction phase Cycle 1, Day 9 and the area under the plasma concentration-time curve during dosing interval at steady state (AUCtauss) of geometric means are reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.

    Time frame: Induction phase Cycle 1, Day 8 to Cycle 1, Day 21 (each cycle 28 days)

  5. Pharmacokinetic Parameter Time of Maximum Plasma Concentration (Tmax) of Quizartinib and the Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

    The time of maximum plasma concentration (Tmax) of geometric means is reported at Induction phase Cycle 1, Day 9 and the time of maximum plasma concentration at steady state (Tmax,ss) of geometric means is reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.

    Time frame: Induction phase Cycle 1, Day 8 to Cycle 1, Day 21 (each cycle 28 days)

  6. Pharmacokinetic Parameter Metabolite to Parent Ratio (MR) of Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

    The metabolite to parent ratio of geometric means for Cmax and AUCtau is reported at Induction phase Cycle 1, Day 9 for active metabolite AC886 is reported.

    Time frame: Induction phase Cycle 1, Day 8 (each cycle 28 days)

  7. Pharmacokinetic Parameter Trough Plasma Concentration (Ctrough) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

    The trough plasma concentration (Ctrough) of geometric means is reported at Induction phase Cycle 1, Day 21 for serum quizartinib, active metabolite AC886, and quizartinib and AC886.

    Time frame: Induction phase Cycle 1, Day 21 (each cycle 28 days)

  8. Pharmacokinetic Parameter Accumulation Ratio (AR) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

    The accumulation ratio of geometric means for Cmax and AUCtau is reported at Induction phase Cycle 1, Day 21 for serum quizartinib, active metabolite AC886, and quizartinib and AC886.

    Time frame: Induction phase Cycle 1, Day 21 (each cycle 28 days)

  9. Number of Participants Treatment-Emergent Adverse Events Reported During Induction Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

    A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that emerges (or worsens) from the first dose of study drug and coadministered drugs to the follow-up visit, 35 days after the last dose of study drug and coadministered drugs, or the start date of new AML post-treatment, whichever was earlier.

    Time frame: Induction phase Cycle 1, Day 1 up to 35 days after last dose in Cycle 2 (each cycle 28 days), up to approximately 1 year

  10. Number of Participants Treatment-Emergent Adverse Events Reported During Consolidation Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

    A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that emerges (or worsens) from the first dose of study drug and coadministered drugs to the follow-up visit, 35 days after the last dose of study drug and coadministered drugs, or the start date of new AML post-treatment, whichever was earlier.

    Time frame: Consolidation phase Cycle 1, Day 1 up to 35 days after last dose (each cycle 28 days), up to approximately 1 year

07

Results

Posted Aug 19, 2021

Participant flow

A total of 7 participants who met all inclusion and no exclusion criteria were enrolled and received treatment in the study.

Induction Phase
Participant flow — Induction Phase
MilestoneQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Started43
Completed21
Not completed22
Withdrew: Progressive disease01
Withdrew: Cr, crp, or cri not achieved (induction cycle 2)20
Withdrew: Relapse after cr, crp, or cri01
Consolidation Phase
Participant flow — Consolidation Phase
MilestoneQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Started21
Completed10
Not completed11
Withdrew: Physician decision11

Outcome measures

PrimarySummary of Best Responses After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Best response was defined as the best measured complete remission (CR), CR with incomplete hematological recovery (CRi), CR with incomplete platelet recovery (CRp), Partial remission (PR), or No response (NR) in the overall response assessments at all time points after the first dose. CR is defined as absence of leukemia cells morphologically; bone marrow blasts \<5 %; neutrophil count ≥ 1000 /mm 3; platelet count ≥ 100 ,000 /mm 3, independence of RBC transfusions for 4 weeks; independence of platelet transfusions for 1 week; absence of extramedullary leukemia.

Time frame:
Day 0 to Day 21 of last completed cycle (each cycle 28 days), up to approximately 1 year
Reported as:
Count of participants · Participants
Summary of Best Responses After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
ParticipantsQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Complete remission (CR)00
CR with incomplete platelet recovery (CRp)00
CR with incomplete hematological recovery (CRi)32
Partial remission (PR)10
No response (NR)01
PrimarySummary of Best Response Rates After the First Oral Dose of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Best response was defined as the best measured complete remission (CR), CR with incomplete hematological recovery (CRi), CR with incomplete platelet recovery (CRp), Partial remission (PR), or No response (NR) in the overall response assessments at all time points after the first dose.

Time frame:
Day 0 to Day 21 of last completed cycle (each cycle 28 days), up to approximately 1 year
Reported as:
Number · percentage of participants
Summary of Best Response Rates After the First Oral Dose of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
percentage of participantsQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Composite CR rate (CRc rate: CR+CRp+CRi)75.0 (30.1 to 95.4)66.7 (20.8 to 93.9)
Response rate (CRc+PR)100 (51.0 to 100.0)66.7 (20.8 to 93.9)
PrimaryPharmacokinetic Parameter Maximum Serum Concentration (Cmax) of Geometric Means of Quizartinib and Active Metabolite (AC886) After Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia

The maximum serum plasma concentration (Cmax) is reported at Induction phase Cycle 1, Day 9 and the maximum serum plasma concentration at steady state (Cmax,ss) is reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.

Time frame:
Induction phase Cycle 1, Day 8 to Cycle 1, Day 21 (each cycle 28 days)
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) of Geometric Means of Quizartinib and Active Metabolite (AC886) After Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
ng/mLQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Cycle 1, Day 8: Quizartinib, Cmax42.4 ± 25.791.3 ± 28.5
Cycle 1, Day 8: AC886, Cmax36.5 ± 25.4103 ± 37.0
Cycle 1, Day 8: Quizartinib + AC886, Cmax77.4 ± 10.3180 ± 16.0
Cycle 1, Day 21: Quizartinib, Cmax, ss64.2 ± 64.0212 ± 47.4
Cycle 1, Day 21: AC886, Cmax, ss96.7 ± 23.7256 ± 45.0
Cycle 1, Day 21: Quizartinib + AC886, Cmax162 ± 35.3480 ± 2.4
PrimaryPharmacokinetic Parameter Area Under the Concentration-Time Curve During Dosing Interval of Quizartinib and Metabolite (AC886) After Daily Dose of 20 mg or 40 mg With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia

The area under the plasma concentration-time curve during dosing interval (AUCtau) of geometric means is reported at Induction phase Cycle 1, Day 9 and the area under the plasma concentration-time curve during dosing interval at steady state (AUCtauss) of geometric means are reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.

Time frame:
Induction phase Cycle 1, Day 8 to Cycle 1, Day 21 (each cycle 28 days)
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetic Parameter Area Under the Concentration-Time Curve During Dosing Interval of Quizartinib and Metabolite (AC886) After Daily Dose of 20 mg or 40 mg With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
ng*h/mLQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Cycle 1, Day 8: Quizartinib, AUCtau418 ± 50.4921 ± 31.3
Cycle 1, Day 8: AC886, AUCtau555 ± 28.81640 ± 24.4
Cycle 1, Day 8: Quizartinib + AC886, AUCtau1010 ± 26.92640 ± 8.0
Cycle 1, Day 21: Quizartinib, AUCtau,ss991 ± 87.72940 ± 76.6
Cycle 1, Day 21: AC886, AUCtau, ss1940 ± 25.45310 ± 40.6
Cycle 1, Day 21: Quizartinib + AC886, AUCtau3020 ± 42.38850 ± 0.3
PrimaryPharmacokinetic Parameter Time of Maximum Plasma Concentration (Tmax) of Quizartinib and the Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

The time of maximum plasma concentration (Tmax) of geometric means is reported at Induction phase Cycle 1, Day 9 and the time of maximum plasma concentration at steady state (Tmax,ss) of geometric means is reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.

Time frame:
Induction phase Cycle 1, Day 8 to Cycle 1, Day 21 (each cycle 28 days)
Reported as:
Median · hour
Pharmacokinetic Parameter Time of Maximum Plasma Concentration (Tmax) of Quizartinib and the Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
hourQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Cycle 1, Day 8: Quizartinib, Tmax3.03 (1.05 to 6.03)2.17 (2.07 to 4.17)
Cycle 1, Day 8: AC886, Tmax5.01 (2.05 to 6.03)6.08 (4.03 to 6.17)
Cycle 1, Day 8: Quizartinib + AC886, Tmax4.01 (2.05 to 6.03)4.17 (4.03 to 6.17)
Cycle 1, Day 21: Quizartinib, Tmax,ss4.03 (2.03 to 4.13)4.08 (4.05 to 4.12)
Cycle 1, Day 21: AC886, Tmax,ss5.02 (2.08 to 5.98)6.09 (6.05 to 6.13)
Cycle 1, Day 21: Quizartinib + AC886, Tmax4.03 (2.08 to 5.93)4.08 (4.05 to 4.12)
PrimaryPharmacokinetic Parameter Metabolite to Parent Ratio (MR) of Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

The metabolite to parent ratio of geometric means for Cmax and AUCtau is reported at Induction phase Cycle 1, Day 9 for active metabolite AC886 is reported.

Time frame:
Induction phase Cycle 1, Day 8 (each cycle 28 days)
Reported as:
Geometric mean · metabolite to parent ratio
Pharmacokinetic Parameter Metabolite to Parent Ratio (MR) of Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
metabolite to parent ratioQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Cycle 1, Day 8: MR (Cmax)0.861 ± 43.81.13 ± 45.6
Cycle 1, Day 8: MR (AUCtau)1.33 ± 64.11.78 ± 56.4
PrimaryPharmacokinetic Parameter Trough Plasma Concentration (Ctrough) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

The trough plasma concentration (Ctrough) of geometric means is reported at Induction phase Cycle 1, Day 21 for serum quizartinib, active metabolite AC886, and quizartinib and AC886.

Time frame:
Induction phase Cycle 1, Day 21 (each cycle 28 days)
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter Trough Plasma Concentration (Ctrough) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
ng/mLQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Cycle 1, Day 21: Quizartinib22.7 ± 173.477.1 ± 117.6
Cycle 1, Day 21: AC88668.6 ± 49.3195 ± 46.1
Cycle 1, Day 21: Quizartinib + AC88694.6 ± 68.5299 ± 3.3
PrimaryPharmacokinetic Parameter Accumulation Ratio (AR) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

The accumulation ratio of geometric means for Cmax and AUCtau is reported at Induction phase Cycle 1, Day 21 for serum quizartinib, active metabolite AC886, and quizartinib and AC886.

Time frame:
Induction phase Cycle 1, Day 21 (each cycle 28 days)
Reported as:
Geometric mean · accumulation ratio
Pharmacokinetic Parameter Accumulation Ratio (AR) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
accumulation ratioQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Cycle 1, Day 21: Quizartinib AR (Cmax)1.52 ± 72.11.98 ± 58.5
Cycle 1, Day 21: AC886 AR (Cmax)2.65 ± 46.92.55 ± 7.2
Cycle 1, Day 21: Quizartinib + AC886 AR (Cmax)2.09 ± 41.62.53 ± 16.2
Cycle 1, Day 21: Quizartinib AR (AUCtau)2.37 ± 88.52.84 ± 36.2
Cycle 1, Day 21: AC886 AR (AUCtau)3.50 ± 56.23.31 ± 5.4
Cycle 1, Day 21: Quizartinib + AC886 AR (AUCtau)2.99 ± 59.53.24 ± 6.8
PrimaryNumber of Participants Treatment-Emergent Adverse Events Reported During Induction Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that emerges (or worsens) from the first dose of study drug and coadministered drugs to the follow-up visit, 35 days after the last dose of study drug and coadministered drugs, or the start date of new AML post-treatment, whichever was earlier.

Time frame:
Induction phase Cycle 1, Day 1 up to 35 days after last dose in Cycle 2 (each cycle 28 days), up to approximately 1 year
Reported as:
Count of participants · Participants
Number of Participants Treatment-Emergent Adverse Events Reported During Induction Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
ParticipantsQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Participants with TEAEs43
Infections and Infestations13
Pneumonia11
Skin infection01
Staphylococcal bacteraemia01
Blood and Lymphatic System Disorders43
Febrile neutropenia43
Anaemia21
Leukopenia10
Neutropenia10
Thrombocytopenia10
Immune Disorders01
Hypersensitivity01
Metabolism and Nutrition Disorders32
Decreased appetite31
Hypoalbuminaemia11
Hypokalaemia20
Hypomagnesaemia10
Hyponatraemia10
Hypophosphataemia10
Hypouricaemia01
Tumour lysis syndrome10
Nervous System Disorders21
Dysgeusia21
Dizziness10
Eye Disorders10
Photophobia10
Cardiac Disorders01
Palpitations01
Vascular Disorders01
Hypotension01
Respiratory, Thoracic, and Mediastinal Disorders01
Epistaxis01
Oropharyngeal pain01
Respiratory disorder01
Gastrointestinal Disorders33
Abdominal pain upper31
Nausea22
Constipation12
Diarrhoea12
Stomatitis21
Cheilitis11
Vomiting11
Melaena01
Hepatobiliary Disorders01
Hepatic function abnormal01
Skin and Subcutaneous Tissue Disorders43
Alopecia32
Rash12
Rash maculo-papular11
Dermatitis bullous01
Dry skin01
Musculoskeletal and Connective Tissue Disorders13
Arthralgia02
Musculoskeletal pain01
Myalgia10
Pain in extremity01
Renal and Urinary Disorders10
Haematuria10
Proteinuria10
Urinary tract pain10
Reproductive System and Breast Disorders01
Menorrhagia01
General Disorders & Administration Site Conditions01
Oedema peripheral01
Pyrexia01
Investigations43
Gamma-glutamyltransferase increased31
Alanine aminotransferase increased21
Blood alkaline phosphatase increased11
Electrocardiogram QT prolonged02
Platelet count decreased11
Weight decreased11
White blood cell count decreased11
Aspartate aminotransferase10
Aspartate aminotransferase increased01
Blood bilirubin increased10
Blood lactate dehydrogenase increased01
Blood pressure decreased01
Lipase increased01
PrimaryNumber of Participants Treatment-Emergent Adverse Events Reported During Consolidation Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that emerges (or worsens) from the first dose of study drug and coadministered drugs to the follow-up visit, 35 days after the last dose of study drug and coadministered drugs, or the start date of new AML post-treatment, whichever was earlier.

Time frame:
Consolidation phase Cycle 1, Day 1 up to 35 days after last dose (each cycle 28 days), up to approximately 1 year
Reported as:
Count of participants · Participants
Number of Participants Treatment-Emergent Adverse Events Reported During Consolidation Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
ParticipantsQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Participants with TEAEs21
Infections and Infestations11
Lung infection01
Skin infection10
Upper respiratory tract infection10
Blood and Lymphatic System Disorders21
Febrile neutropenia21
Nervous System Disorders10
Dysgeusia10
Gastrointestinal Disorders20
Diarrhoea20
Nausea10
Stomatitis10
Skin and Subcutaneous Tissue Disorders11
Rash10
Rash maculo-papular01
General Disorders & Administration Site Conditions10
Oedema peripheral10
Investigations21
Platelet count decreased11
White blood cell count decreased11
Alanine aminotransferase increased10
Electrocardiogram QT prolonged01
Injury, Poisoning, and Procedural Complications01
Contusion01
Fall01

Adverse events

Collected over Adverse events (AEs) were collected from Induction phase Cycle 1, Day 1 up to 35 days after last completed cycle in Consolidation phase, up to approximately 1 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Quizartinib 20 mg/Day0/4 (0%)0/4 (0%)4/4 (100%)
Quizartinib 40 mg/Day0/3 (0%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventQuizartinib 20 mg/DayQuizartinib 40 mg/Day
PneumoniaInfections and infestations0/41/3
Staphylococcal bacteraemiaInfections and infestations0/41/3
Most frequent other events
Showing 10 of 65
Most frequent other events
EventQuizartinib 20 mg/DayQuizartinib 40 mg/Day
Febrile neutropeniaBlood and lymphatic system disorders4/43/3
Electrocardiogram QT prolongedInvestigations0/43/3
Decreased appetiteMetabolism and nutrition disorders3/41/3
DysgeusiaNervous system disorders3/41/3
DiarrhoeaGastrointestinal disorders3/42/3
NauseaGastrointestinal disorders3/42/3
Abdominal pain upperGastrointestinal disorders3/41/3
StomatitisGastrointestinal disorders3/41/3
AlopeciaSkin and subcutaneous tissue disorders3/42/3
Gamma-glutamyltransferase increasedInvestigations3/41/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Quizartinib 20 mg/DayQuizartinib 40 mg/DayTotal
<=18 years000
Between 18 and 65 years224
>=65 years213
Age, Continuous
Age, Continuous(years)Quizartinib 20 mg/DayQuizartinib 40 mg/DayTotal
Mean57.5 ± 10.553.7 ± 17.155.9 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Quizartinib 20 mg/DayQuizartinib 40 mg/DayTotal
Female224
Male213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Quizartinib 20 mg/DayQuizartinib 40 mg/DayTotal
American Indian or Alaska Native000
Asian437
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Quizartinib 20 mg/DayQuizartinib 40 mg/DayTotal
Japan437
08

Study locations

1 site
  • Tokyo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Oct 2017, 14 months.

Results were first posted in Aug 2021, 3 years 10 months after primary completion.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 14 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2016
First posted
Jul 15, 2016
StartActual
Aug 12, 2016
Primary completionActual
Oct 19, 2017
CompletionActual
Oct 19, 2017
Results first posted
Aug 19, 2021
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02834390
Responsible party
Sponsor
First posted
Jul 15, 2016
Start date
Aug 12, 2016
Primary completion
Oct 19, 2017
Completion
Oct 19, 2017
Results posted
Aug 19, 2021
Last update
Mar 5, 2025

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quizartinib

Start the discussion